Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionExtended release fixed-dose combination of MK-0524A and simvastatin
Molecular Target Prostaglandin D2 (PGD2) receptor subtype DP1 (PTGDR1) (DP1) ; HMG-CoA reductase
Mechanism of ActionProstaglandin D2 (PGD2) receptor subtype DP2 (CRTH2) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationAtherosclerosis
Indication DetailsTreat atherosclerosis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today